Role of Oral Chlorhexidine Gel in Prevention of Ventilator Associated Pneumonia
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if oral mucosal application of chlorhexidine gel will prevent the development of ventilator associated pneumonia in children.
| Condition | Intervention | Phase |
|---|---|---|
|
Ventilator Associated Pneumonia |
Drug: Chlorhexidine gel Drug: Placebo gel |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Prevention |
| Official Title: | Oral Mucosal Decontamination With Chlorhexidine for Prevention of Ventilator Associated Pneumonia in Children - A Randomized Controlled Trial |
- Occurrence of ventilator associated pneumonia as defined by CDC diagnostic criteria [ Time Frame: 21 days ] [ Designated as safety issue: No ]
- Antibiotic sensitivity of organism cultured [ Time Frame: 21 days ] [ Designated as safety issue: No ]
- Duration of hospital stay [ Time Frame: 21 days ] [ Designated as safety issue: No ]
- Duration of ICU stay [ Time Frame: 21 days ] [ Designated as safety issue: No ]
- In hospital mortality rate [ Time Frame: 21 days ] [ Designated as safety issue: No ]
| Enrollment: | 86 |
| Study Start Date: | November 2007 |
| Study Completion Date: | April 2009 |
| Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Chlorhexidine gel
|
Drug: Chlorhexidine gel
Oral mucosal application of chlorhexidine gel
|
|
Placebo Comparator: 2
Placebo gel
|
Drug: Placebo gel
Oral mucosal application of placebo gel
|
Detailed Description:
Ventilator associated pneumonia as the name suggests refers to pneumonia occurring in the setting of mechanical ventilation. It accounts of 86% of nosocomial pneumonia and in contrast to other more common nosocomial infections is accompanied by a mortality rate of upto 76% in certain settings. A number of preventive methods have been studied to reduce the rate of VAP but a consensus is lacking with regards to appropriate preventive strategies. Studies in adults have shown a beneficial effect of oral mucosal application of chlorhexidine but similar studies in pediatric population are not available. This research project aims at addressing the gap.
Eligibility| Ages Eligible for Study: | 3 Months to 15 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Patients in PICU requiring mechanical ventilation
- Above the age of 3 months
- Oro or nasotracheal intubation
Exclusion criteria:
- Known hypersensitivity to chlorhexidine
- Inability to access the oral cavity for any reason
- Patients with tracheostomy
- Mechanical ventilation for more than 24 hours prior to PICU admission.
- Death or extubation within 24 hours of ICU admission.
Contacts and Locations| India | |
| All India Institute of Medical Sciences | |
| New Delhi, Delhi, India, 110029 | |
| Study Director: | RAKESH LODHA | All India Institute of Medical Sciences, New Delhi |
More Information
No publications provided by All India Institute of Medical Sciences, New Delhi
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Meghna Raju Sebastian, All India Institute of Medical Sciences |
| ClinicalTrials.gov Identifier: | NCT00597688 History of Changes |
| Other Study ID Numbers: | Meghna |
| Study First Received: | January 10, 2008 |
| Last Updated: | March 22, 2011 |
| Health Authority: | India: Institutional Review Board |
Additional relevant MeSH terms:
|
Pneumonia Pneumonia, Ventilator-Associated Lung Diseases Respiratory Tract Diseases Respiratory Tract Infections Cross Infection Infection Ventilator-Induced Lung Injury Lung Injury |
Chlorhexidine Chlorhexidine gluconate Anti-Infective Agents, Local Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Disinfectants Dermatologic Agents |
ClinicalTrials.gov processed this record on May 22, 2013